Peptidylprolyl isomerase A pseudogene 13 (PPIAP13)

Peptidylprolyl isomerase A pseudogene 13 is a non-protein-coding pseudogene homologous to the *peptidylprolyl isomerase A* gene. Like other pseudogenes, it may retain regulatory elements or function as a long non-coding RNA, possibly acting as a competitive endogenous RNA to modulate parental gene expression by sequestering microRNAs. However, there is currently no published functional or disease association for PPIAP13 specifically; most literature discusses PPIA pseudogenes in general or specific members (e.g., PPIAP22), some of which may act as miRNA “sponges” and influence cancer progression. PPIAP13 is *not* considered a therapeutic target, does not encode an active enzyme or receptor, and is not documented as a relevant biomarker or drug target[2][5]. Summary for Structured Information Extraction - PPIAP13 is a pseudogene, not a canonical therapeutic target. - Little direct biological or disease-role information is available for PPIAP13 itself. - Some pseudogenes (e.g., PPIAP22, *PTENP1*) regulate gene expression and have disease relevance in cancer via competing endogenous RNA mechanisms[2][5]. - PPIAP13 itself is not a biomarker, not targeted by drugs, and does not pose safety concerns. If you need information about the functional PPIA protein (cyclophilin A), additional details can be provided, but PPIAP13 itself does not represent a druggable molecular target or recognized biomarker[1][3][5].

Other names

Peptidylprolyl isomerase A pseudogene 13PPIAP13

None. PPIAP13 does not act as a protein target for drug mechanisms.